Table 1.
Study characteristics
| First author | Year | Design | Country | Sample Size* | Proportion with NDE (%) | Female (%) | Age | Total follow-up |
|---|---|---|---|---|---|---|---|---|
| Greyson[10] | 2003 | Comparative cohort study | USA | 116 | 10%** | |||
| Klemenc-Ketis[35] | 2010 | Cohort study | Slovenia | 52 | 11 (21.2%) | 10 (19.2) | Median 53.1 (SD: 14.5) | Nil |
| Klemenc-Ketis[36] | 2011 | Cohort study | Slovenia | 52 | 11 (21.2%) | 10 (19.2%) | Median 53.1 (SD: 14.5) | Nil |
| Klemenc-Ketis[7] | 2013 | Cohort study | Slovenia | 37 | 7 (18.9%) | 8 (21.6%) | Mean 54 (SD: 13.1) | 6 months |
| Parnia[12] | 2001 | Cohort study | UK | 63 | 4 (6.3%)** | Nil | ||
| Parnia[16] | 2014 | Cohort study | International | 140 | 9 (6.4%)** | 45 (33%) | Mean 64 (SD: 13) | 3 months to 1 year |
| Parnia[17] | 2023 | Cohort | International | 28 | 11 (39.3%)** | 4 (14.3%) | Mean 63.6 (SD: 13.7) | Discharge or death |
| Schwaninger[11] | 2002 | Cohort study | USA | 30 | 7 (23%)** | 15 (50%) | Mean 60 (range: 23–86) | 6 months |
| Sterz[14] | 2023 | Cohort study | Austria | 126 | 20 (15.9%) | 9 (45%) | Mean 58.7 | 553 days |
| Van Lommel[2] | 2001 | Cohort study | Netherlands | 344 | 62 (18%) | 93 (27%) | Mean 62.2 (SD: 12.2) | 2 years |
| Zingmark[15] | 2022 | Cohort study | Sweden | 30 | 5 (16.7%) | 0 (%) | 10 weeks |
**Deemed an ‘experiencer’ with a score of 7 or greater on Greyson’s near-death experience scale[3]